AI Article Synopsis
- - Arterial hypertension (AH) is the most prevalent cardiovascular risk factor, particularly affecting patients undergoing cancer treatments, and it significantly increases the risk of treatment-related heart issues.
- - Uncontrolled AH, whether existing prior to or developing during cancer therapy, can negatively impact the health outcomes of cancer patients, especially in those with heart-related organ damage (HMOD).
- - Clinicians caring for cancer patients should prioritize managing AH and HMOD to ensure the effectiveness of anticancer treatments and maintain cardiovascular health.
Article Abstract
Purpose Of The Review: Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD). Influence of AH and HMOD on the development of cardiotoxicity will be reviewed, with a focus on specific scenarios and implications for management of oncologic patients.
Recent Findings: Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977700 | PMC |
| http://dx.doi.org/10.1007/s11897-023-00590-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!